Benitec Biopharma Inc. (BNTC) – SEC staff letter
2026-04-03 · Re: Form 10-K for Fiscal Year Ended June 30, 2025 · Accession 0000000000-26-003380 · Review completed (no further comments)
April 3, 2026 Megan Boston Chief Financial Officer Benitec Biopharma Inc. 3940 Trust Way Hayward, California 94545 Re: Benitec Biopharma Inc. Form 10-K for Fiscal Year Ended June 30, 2025 File No. 001-39267 Dear Megan Boston: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Full letter on EDGAR → · Filing index · All Benitec Biopharma Inc. (BNTC) correspondence
Templates & resources
- AICPA & CIMA – SEC reporting resources (AICPA & CIMA · Professional body · Free / member)
- BDO Accounting, Reporting & Compliance Hub (ARCH) (BDO · Firm guide · Free)
- Deloitte DART – Roadmap Series (Deloitte · Firm guide · Free)
- Deloitte Roadmap: SEC Comment Letter Considerations (Deloitte · Firm guide · Free)
- KPMG Financial Reporting View (KPMG · Firm guide · Free)
- PwC Viewpoint (PwC · Firm guide · Free / paid)
- RSM Financial Reporting Resource Center (RSM · Firm guide · Free)
- SEC – EDGAR Full Text Search (SEC · Regulator · Free)